Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Imdpharm Inc. currently manages 1 pending office action. This matter is located within the Biotechnology & Pharmaceuticals technology area. Having 1 pending office action suggests a focused prosecution phase for the company's current intellectual property interests.
The examination involves 1 distinct examiner and 1 distinct art unit. This concentration in 1 distinct art unit means the technical evaluation is confined to a specific regulatory group. SOROUSH, LAYLA is the busiest examiner for this company and is responsible for 1 pending office action, which matches the total count of pending actions for the portfolio.
Because there is 1 distinct examiner, the company's immediate patent outcomes depend on the specific review style of SOROUSH, LAYLA. The 1 pending office action in the Biotechnology & Pharmaceuticals sector requires a response tailored to this examiner's history. Managing the prosecution with 1 examiner allows for a direct legal strategy without the need to coordinate across different art units.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SOROUSH, LAYLA | 1 | 40.5% | +43.4% |
| DESAI, ANAND U | 1 | 78.2% | +13.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17639908 | COMPOSITION COMPRISING BILBERRY EXTRACT AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING SENSORINEURAL HEARING IMPAIRMENT | DESAI, ANAND U | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17797868 | LIQUID CRYSTALLINE STRUCTURE-FORMING OMEGA-3-FATTY ACID COMPOSITION | SOROUSH, LAYLA | — |
| 17639908 | COMPOSITION COMPRISING BILBERRY EXTRACT AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING SENSORINEURAL HEARING IMPAIRMENT | DESAI, ANAND U | — |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| 1655 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17797868 | LIQUID CRYSTALLINE STRUCTURE-FORMING OMEGA-3-FATTY ACID COMPOSITION | SOROUSH, LAYLA | 1622 | §103 | Final Rejection | — | Pending | Aug 05, 2022 |
| 17639908 | COMPOSITION COMPRISING BILBERRY EXTRACT AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING SENSORINEURAL HEARING IMPAIRMENT | DESAI, ANAND U | 1655 | §102§103 | Final Rejection | — | Pending | Apr 25, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialImdpharm Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Layla Soroush has the most, with 1 of Imdpharm Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
